SCHEMBL3882385

SCHEMBL3882385

Cc1cncc(C(=O)N2CCC(c3nc4c(s3)CCN(C3=CC=C3)CC4)CC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 9/20 0.43
DCUN1D1 Q96GG9 9/20 0.43
LMNA P02545 2/20 0.42
SMYD3 Q9H7B4 1/20 0.35
MAPT P10636 4/20 0.34
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
RECQL P46063 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
GFER P55789 1/20 0.34
TP53 P04637 4/20 0.34
L3MBTL4 Q8NA19 1/20 0.33
L3MBTL3 Q96JM7 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GRM5 P41594 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3880892 0.88 UBE2M (0.57) UBE2MDCUN1D1LMNACYP2C9CYP2C19
SCHEMBL3879365 0.87 UBE2M (0.53) UBE2MDCUN1D1LMNAMAPTMEN1
SCHEMBL3881016 0.86 CYP2C9 (0.42) UBE2MDCUN1D1LMNAMAPTMEN1
SCHEMBL3879404 0.86 UBE2M (0.39) UBE2MDCUN1D1LMNAMAPTMEN1
SCHEMBL3880379 0.86 UBE2M (0.41) UBE2MDCUN1D1LMNAMAPTMEN1
SCHEMBL3879091 0.85 UBE2M (0.41) UBE2MDCUN1D1LMNAMAPTMEN1
SCHEMBL3881507 0.85 GRM5 (0.35) UBE2MDCUN1D1LMNAMAPTMEN1
SCHEMBL3879018 0.84 UBE2M (0.42) UBE2MDCUN1D1LMNAMAPTMEN1
SCHEMBL3882382 0.84 L3MBTL3 (0.44) UBE2MDCUN1D1LMNAMAPTMEN1
SCHEMBL3885757 0.82 GRM5 (0.37) UBE2MDCUN1D1LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP claimed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US claimed
EP-1858900-A1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2007-11-28 EP claimed
WO-2006097691-A1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2006-09-21 WO claimed
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed
EP-1858900-A1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006097691-A1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor HRH3, HRH4, HRH2 UBE2M 4124/4885DCUN1D1 2343/4885LMNA 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.